Medical Imaging for Pediatric Hematologic Cancer Risk
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events - including heart attack, stroke, and cardiovascular death - in adults...
- The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group.
- This finding primarily impacts individuals with obesity *and* pre-existing cardiovascular disease.The SELECT trial specifically enrolled participants with a body mass index (BMI) of 27 or higher, and established...
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death – in adults with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared too those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. while semaglutide demonstrated notable weight loss, the cardiovascular safety signal is prompting a reassessment of its use in this specific patient population.
The Data: Key Findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33,indicating a 33% increased risk. However, it’s crucial to note that the trial did *not* show a statistically significant increase in all-cause mortality. The primary outcome was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
| Outcome | Semaglutide Group (%) | Placebo group (%) | Hazard Ratio |
|---|---|---|---|
| MACE (Cardiovascular Death, MI, Stroke) | 6.5 | 4.9 | 1.33 |
| Cardiovascular Death | 3.7 | 3.2 | 1.16 |
| Nonfatal Myocardial Infarction | 2.6 | 2.2 | 1.18 |
| Nonfatal Stroke | 1.7 | 1.3 | 1.31 |
Who is Affected? Understanding the Patient Population
This finding primarily impacts individuals with obesity *and* pre-existing cardiovascular disease.The SELECT trial specifically enrolled participants with a body mass index (BMI) of 27 or higher, and established cardiovascular disease – meaning a history of heart attack, stroke, or peripheral artery disease. It’s important to emphasize that these results do *not* necessarily apply to individuals using semaglutide for type 2 diabetes management or those with obesity but no prior cardiovascular issues. However, it does raise questions about the long-term cardiovascular effects of these medications in a broader population.
Why This Matters: Beyond Weight Loss
Semaglutide, initially developed for diabetes, gained widespread popularity for its dramatic weight loss effects. The initial enthusiasm was fueled by studies showing potential cardiovascular benefits in diabetic patients. the SELECT trial challenges this narrative, demonstrating that weight loss alone doesn’t guarantee cardiovascular protection, and in some cases, may be accompanied by increased risk. This highlights the complexity of obesity and cardiovascular disease, and the need for a nuanced approach to treatment.